A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer.
Aayah NounuAlexander GreenhoughKate J HeesomRebecca C RichmondJie ZhengStephanie J WeinsteinDemetrius AlbanesJohn A BaronJohn L HopperJane C FigueiredoPolly A NewcombNoralane M LindorGraham CaseyElizabeth A PlatzLoïc Le MarchandCornelia M UlrichChristopher I LiFranzel J B van DuijnhovenAndrea GsurPeter T CampbellVictor MorenoPavel VodickaLudmila VodickovaHermann BrennerJenny Chang-ClaudeMichael HoffmeisterLori C SakodaMartha L SlatteryRobert E SchoenMarc J GunterSergi Castellví-BelHyeong Rok KimSun Seog KweonAndrew T ChanLi LiWei ZhengD Timothy BishopDaniel D BuchananGraham G GilesStephen B GruberGad RennertZsofia K StadlerTabitha A HarrisonYi LinTemitope O KekuMichael O WoodsClemens SchafmayerBethany Van GuelpenSteven GallingerHeather HampelSonja I BerndtPaul D P PharoahAnnika LindblomAlicja WolkAnna H WuEmily WhiteUlrike PetersDavid A DrewDominique SchererJusto Lorenzo BermejoAnn C WilliamsCaroline L ReltonPublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2020)
Our approach has shown how laboratory experiments and population-based approaches can combine to identify aspirin-targeted proteins possibly affecting CRC risk.